Neo-adjuvant chemotherapy followed by radical resection for primary borderline resectable unicentric Castleman disease: a case report

Here we introduced a successful case showing neo-adjuvant chemotherapy followed by radical resection for a borderline resectable unicentric Castleman disease (UCD). This study demonstrated that neo-adjuvant rituximab in combination with cyclophosphamide, epirubicin, vincristine and prednisone (R-CHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuang, Hongkai, Ma, Zuyi, Wu, Yanxia, Yin, Zi, Jian, Zhixiang, Zhang, Chuanzhao, Hou, Baohua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799261/
https://www.ncbi.nlm.nih.gov/pubmed/35117662
http://dx.doi.org/10.21037/tcr.2020.02.45
_version_ 1784642029254344704
author Zhuang, Hongkai
Ma, Zuyi
Wu, Yanxia
Yin, Zi
Jian, Zhixiang
Zhang, Chuanzhao
Hou, Baohua
author_facet Zhuang, Hongkai
Ma, Zuyi
Wu, Yanxia
Yin, Zi
Jian, Zhixiang
Zhang, Chuanzhao
Hou, Baohua
author_sort Zhuang, Hongkai
collection PubMed
description Here we introduced a successful case showing neo-adjuvant chemotherapy followed by radical resection for a borderline resectable unicentric Castleman disease (UCD). This study demonstrated that neo-adjuvant rituximab in combination with cyclophosphamide, epirubicin, vincristine and prednisone (R-CHOP) chemotherapy alleviated the symptom of plasma cell type of Castleman disease (PCCD) as well as downsized the tumor to provide an opportunity for radical surgical resection. It would contribute to the treatment for borderline resectable or unresectable UCD in the future.
format Online
Article
Text
id pubmed-8799261
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-87992612022-02-02 Neo-adjuvant chemotherapy followed by radical resection for primary borderline resectable unicentric Castleman disease: a case report Zhuang, Hongkai Ma, Zuyi Wu, Yanxia Yin, Zi Jian, Zhixiang Zhang, Chuanzhao Hou, Baohua Transl Cancer Res Case Report Here we introduced a successful case showing neo-adjuvant chemotherapy followed by radical resection for a borderline resectable unicentric Castleman disease (UCD). This study demonstrated that neo-adjuvant rituximab in combination with cyclophosphamide, epirubicin, vincristine and prednisone (R-CHOP) chemotherapy alleviated the symptom of plasma cell type of Castleman disease (PCCD) as well as downsized the tumor to provide an opportunity for radical surgical resection. It would contribute to the treatment for borderline resectable or unresectable UCD in the future. AME Publishing Company 2020-04 /pmc/articles/PMC8799261/ /pubmed/35117662 http://dx.doi.org/10.21037/tcr.2020.02.45 Text en 2020 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
spellingShingle Case Report
Zhuang, Hongkai
Ma, Zuyi
Wu, Yanxia
Yin, Zi
Jian, Zhixiang
Zhang, Chuanzhao
Hou, Baohua
Neo-adjuvant chemotherapy followed by radical resection for primary borderline resectable unicentric Castleman disease: a case report
title Neo-adjuvant chemotherapy followed by radical resection for primary borderline resectable unicentric Castleman disease: a case report
title_full Neo-adjuvant chemotherapy followed by radical resection for primary borderline resectable unicentric Castleman disease: a case report
title_fullStr Neo-adjuvant chemotherapy followed by radical resection for primary borderline resectable unicentric Castleman disease: a case report
title_full_unstemmed Neo-adjuvant chemotherapy followed by radical resection for primary borderline resectable unicentric Castleman disease: a case report
title_short Neo-adjuvant chemotherapy followed by radical resection for primary borderline resectable unicentric Castleman disease: a case report
title_sort neo-adjuvant chemotherapy followed by radical resection for primary borderline resectable unicentric castleman disease: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799261/
https://www.ncbi.nlm.nih.gov/pubmed/35117662
http://dx.doi.org/10.21037/tcr.2020.02.45
work_keys_str_mv AT zhuanghongkai neoadjuvantchemotherapyfollowedbyradicalresectionforprimaryborderlineresectableunicentriccastlemandiseaseacasereport
AT mazuyi neoadjuvantchemotherapyfollowedbyradicalresectionforprimaryborderlineresectableunicentriccastlemandiseaseacasereport
AT wuyanxia neoadjuvantchemotherapyfollowedbyradicalresectionforprimaryborderlineresectableunicentriccastlemandiseaseacasereport
AT yinzi neoadjuvantchemotherapyfollowedbyradicalresectionforprimaryborderlineresectableunicentriccastlemandiseaseacasereport
AT jianzhixiang neoadjuvantchemotherapyfollowedbyradicalresectionforprimaryborderlineresectableunicentriccastlemandiseaseacasereport
AT zhangchuanzhao neoadjuvantchemotherapyfollowedbyradicalresectionforprimaryborderlineresectableunicentriccastlemandiseaseacasereport
AT houbaohua neoadjuvantchemotherapyfollowedbyradicalresectionforprimaryborderlineresectableunicentriccastlemandiseaseacasereport

Ejemplares similares